Evidence map›Paper›PMID 33976384›Full record

ReviewNature reviews. Drug discovery2021

Targeting inflammation in atherosclerosis - from experimental insights to the clinic.

Oliver Soehnlein, Peter Libby

Registry-linked trialOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nature reviews. Drug discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06860295 (The Architectural Immunoregulation in Atherosclerotic Disease), which is not on this map. Cited by 595 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
595citing papers in PubMed, 4 pooled it
54.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06860295 not yet recruitingnot on this mapstarted 2025, after this paper: background citation

The Architectural Immunoregulation in Atherosclerotic Disease: A Single-Cell RNA Sequencing and Spatial Biology Approach

Typeobservational_patient_registrySponsorHospital Israelita Albert EinsteinRan2025 to 2027Enrolled30ConditionsAtherosclerosis of Coronary ArteryArmsSingle Cell RNA Sequencing
3 · Its place in the literature

Who cites it

595 citing papers in PubMed, 4 syntheses or guidelines pooled it, 945 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

535 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 3 countries.

Oliver SoehnleinInstitute for Experimental Pathology, Center for Molecular Biology of Inflammation, Westfälische Wilhelms-Universität, Münster, Germany. soehnlein@uni-muenster.de.ORCID http://orcid.org/0000-0002-7854-0694
Peter LibbyBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-1502-502X
Brigham and Women's Hospital · USUniversity of Münster · DE

Funding

Novel mechanisms of the thrombotic complications of atherosclerosisR01HL134892 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI LIBBY, PETER · 2019 to 2022
$1.7M
NHLBI NIH HHS R01 HL134892
6 · The paper itself

Abstract

Atherosclerosis, a dominant and growing cause of death and disability worldwide, involves inflammation from its inception to the emergence of complications. Targeting inflammatory pathways could therefore provide a promising new avenue to prevent and treat atherosclerosis. Indeed, clinical studies have now demonstrated unequivocally that modulation of inflammation can forestall the clinical complications of atherosclerosis. This progress pinpoints the need for preclinical investigations to refine strategies for combatting inflammation in the human disease. In this Review, we consider a gamut of attractive possibilities for modifying inflammation in atherosclerosis, including targeting pivotal inflammatory pathways such as the inflammasomes, inhibiting cytokines, manipulating adaptive immunity and promoting pro-resolution mechanisms. Along with lifestyle measures, pharmacological interventions to mute inflammation could complement traditional targets, such as lipids and hypertension, to make new inroads into the management of atherosclerotic risk.

Indexed as

Anti-Inflammatory AgentsAtherosclerosisClinical Trials as TopicHumansImmunity, InnateInflammationAnti-Inflammatory Agents

Identifiers

PMID33976384
PMCPMC8112476
OpenAlexW3163123861

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.